| ■ 영문 제목 : Global Bispecific Antibodies for Cancer Market 2023-2027
|
 | ■ 상품코드 : IRTNTR72677-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 2월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,375,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사의 본 연구 보고서에 따르면 세계의 암치료용 이중특이성 항체 시장 규모가 2022년에서 2027년 사이에 400.72백만 달러에 이르며, 예측 기간 동안 연평균 8.82% 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 암치료용 이중특이성 항체 시장에 대해서 조사및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 종류별 (CD19/CD3, CD30/CD16A) 분석, 유통 채널별 (병원, 소매 약국, 온라인) 분석, 고객 현황, 지역별 현황 (북미, 아시아 태평양, 유럽, 중동 및 아프리카, 남미, 미국, 아일랜드, 중국, 헝가리, 인도) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC. 와 같은 기업 정보를 포함하고 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 암치료용 이중특이성 항체 시장 규모 : 종류별
- CD19/CD3의 시장 규모
- CD30/CD16A의 시장 규모
・세계의 암치료용 이중특이성 항체 시장 규모 : 유통 채널별
- 병원 채널의 시장 규모
- 소매 약국 채널의 시장 규모
- 온라인 채널의 시장 규모
・고객 현황
・지역별 현황
- 북미의 암치료용 이중특이성 항체 시장 규모
- 유럽의 암치료용 이중특이성 항체 시장 규모
- 아시아 태평양의 암치료용 이중특이성 항체 시장 규모
- 기타 지역의 암치료용 이중특이성 항체 시장 규모
- 아일랜드의 암치료용 이중특이성 항체 시장 규모
- 중국의 암치료용 이중특이성 항체 시장 규모
- 헝가리 암치료용 이중특이성 항체 시장 규모
- 인도의 암치료용 이중특이성 항체 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 암치료용 이중특이성 항체 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 암치료용 이중특이성 항체 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Bispecific Antibodies for Cancer Market 2023-2027Technavio has been monitoring the bispecific antibodies for cancer market and is forecast to grow by $400.72 mn during 2022-2027, accelerating at a CAGR of 8.82% during the forecast period. Our report on the bispecific antibodies for cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, advantages of bispecific antibodies over monoclonal antibodies, and strong pipeline.
Technavio’s bispecific antibodies for cancer market is segmented as below:
By Type
• CD19 or CD3
• CD30 or CD16A
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the emerging bispecific antibody generation platforms as one of the prime reasons driving the bispecific antibodies for cancer market growth during the next few years. Also, increase in strategic alliances. and strong R&D in China will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the bispecific antibodies for cancer market covers the following areas:
• Bispecific antibodies for cancer market sizing
• Bispecific antibodies for cancer market forecast
• Bispecific antibodies for cancer market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bispecific antibodies for cancer market vendors that include ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc. Also, the bispecific antibodies for cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global bispecific antibodies for cancer market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global bispecific antibodies for cancer market 2017 – 2021 ($ million)
o 4.2 Type Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type – Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 CD19 or CD3 – Market size and forecast 2022-2027
o Exhibit 34: Chart on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
o 6.4 CD30 or CD16A – Market size and forecast 2022-2027
o Exhibit 38: Chart on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 44: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 46: Chart on Comparison by Distribution Channel
o Exhibit 47: Data Table on Comparison by Distribution Channel
o 7.3 Hospitals – Market size and forecast 2022-2027
o Exhibit 48: Chart on Hospitals – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Hospitals – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Hospitals – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Hospitals – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 52: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online – Market size and forecast 2022-2027
o Exhibit 56: Chart on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Online – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Online – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 60: Market opportunity by Distribution Channel ($ million)
o Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share by geography 2022-2027 (%)
o Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 67: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 83: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Ireland – Market size and forecast 2022-2027
o Exhibit 87: Chart on Ireland – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Ireland – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Ireland – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Ireland – Year-over-year growth 2022-2027 (%)
o 9.9 China – Market size and forecast 2022-2027
o Exhibit 91: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.10 Hungary – Market size and forecast 2022-2027
o Exhibit 95: Chart on Hungary – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Hungary – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Hungary – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Hungary – Year-over-year growth 2022-2027 (%)
o 9.11 India – Market size and forecast 2022-2027
o Exhibit 99: Chart on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on India – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on India – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 103: Market opportunity by geography ($ million)
o Exhibit 104: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 ABL Bio Inc.
o Exhibit 111: ABL Bio Inc. – Overview
o Exhibit 112: ABL Bio Inc. – Product / Service
o Exhibit 113: ABL Bio Inc. – Key offerings
o 12.4 AFFIMED N.V.
o Exhibit 114: AFFIMED N.V. – Overview
o Exhibit 115: AFFIMED N.V. – Product / Service
o Exhibit 116: AFFIMED N.V. – Key offerings
o 12.5 Akeso Inc.
o Exhibit 117: Akeso Inc. – Overview
o Exhibit 118: Akeso Inc. – Product / Service
o Exhibit 119: Akeso Inc. – Key offerings
o 12.6 Amgen Inc.
o Exhibit 120: Amgen Inc. – Overview
o Exhibit 121: Amgen Inc. – Product / Service
o Exhibit 122: Amgen Inc. – Key offerings
o 12.7 Aptevo Therapeutics Inc.
o Exhibit 123: Aptevo Therapeutics Inc. – Overview
o Exhibit 124: Aptevo Therapeutics Inc. – Product / Service
o Exhibit 125: Aptevo Therapeutics Inc. – Key offerings
o 12.8 Astellas Pharma Inc.
o Exhibit 126: Astellas Pharma Inc. – Overview
o Exhibit 127: Astellas Pharma Inc. – Product / Service
o Exhibit 128: Astellas Pharma Inc. – Key offerings
o 12.9 Chugai Pharmaceutical Co. Ltd.
o Exhibit 129: Chugai Pharmaceutical Co. Ltd. – Overview
o Exhibit 130: Chugai Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 131: Chugai Pharmaceutical Co. Ltd. – Key offerings
o 12.10 Eli Lilly and Co.
o Exhibit 132: Eli Lilly and Co. – Overview
o Exhibit 133: Eli Lilly and Co. – Product / Service
o Exhibit 134: Eli Lilly and Co. – Key offerings
o 12.11 EPIMAB BIOTHERAPEUTICS INC.
o Exhibit 135: EPIMAB BIOTHERAPEUTICS INC. – Overview
o Exhibit 136: EPIMAB BIOTHERAPEUTICS INC. – Product / Service
o Exhibit 137: EPIMAB BIOTHERAPEUTICS INC. – Key offerings
o 12.12 F STAR THERAPEUTICS INC.
o Exhibit 138: F STAR THERAPEUTICS INC. – Overview
o Exhibit 139: F STAR THERAPEUTICS INC. – Product / Service
o Exhibit 140: F STAR THERAPEUTICS INC. – Key offerings
o 12.13 F. Hoffmann La Roche Ltd.
o Exhibit 141: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 142: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 143: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 144: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 145: F. Hoffmann La Roche Ltd. – Segment focus
o 12.14 Glenmark Pharmaceuticals Ltd.
o Exhibit 146: Glenmark Pharmaceuticals Ltd. – Overview
o Exhibit 147: Glenmark Pharmaceuticals Ltd. – Product / Service
o Exhibit 148: Glenmark Pharmaceuticals Ltd. – Key offerings
o 12.15 Johnson and Johnson
o Exhibit 149: Johnson and Johnson – Overview
o Exhibit 150: Johnson and Johnson – Business segments
o Exhibit 151: Johnson and Johnson – Key news
o Exhibit 152: Johnson and Johnson – Key offerings
o Exhibit 153: Johnson and Johnson – Segment focus
o 12.16 Mereo BioPharma Group Plc
o Exhibit 154: Mereo BioPharma Group Plc – Overview
o Exhibit 155: Mereo BioPharma Group Plc – Product / Service
o Exhibit 156: Mereo BioPharma Group Plc – Key offerings
o 12.17 Merus N.V.
o Exhibit 157: Merus N.V. – Overview
o Exhibit 158: Merus N.V. – Product / Service
o Exhibit 159: Merus N.V. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 160: Inclusions checklist
o Exhibit 161: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 162: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 163: Research methodology
o Exhibit 164: Validation techniques employed for market sizing
o Exhibit 165: Information sources
o 13.5 List of abbreviations
o Exhibit 166: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global bispecific antibodies for cancer market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Type – Market share 2022-2027 (%)
Exhibits31: Data Table on Type – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Hospitals – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Hospitals – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Hospitals – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Hospitals – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Online – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Online – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Online – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Online – Year-over-year growth 2022-2027 (%)
Exhibits60: Market opportunity by Distribution Channel ($ million)
Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share by geography 2022-2027 (%)
Exhibits64: Data Table on Market share by geography 2022-2027 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Ireland – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Ireland – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Ireland – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Ireland – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Hungary – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Hungary – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Hungary – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Hungary – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on India – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on India – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on India – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on India – Year-over-year growth 2022-2027 (%)
Exhibits103: Market opportunity by geography ($ million)
Exhibits104: Data Tables on Market opportunity by geography ($ million)
Exhibits105: Impact of drivers and challenges in 2022 and 2027
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: ABL Bio Inc. – Overview
Exhibits112: ABL Bio Inc. – Product / Service
Exhibits113: ABL Bio Inc. – Key offerings
Exhibits114: AFFIMED N.V. – Overview
Exhibits115: AFFIMED N.V. – Product / Service
Exhibits116: AFFIMED N.V. – Key offerings
Exhibits117: Akeso Inc. – Overview
Exhibits118: Akeso Inc. – Product / Service
Exhibits119: Akeso Inc. – Key offerings
Exhibits120: Amgen Inc. – Overview
Exhibits121: Amgen Inc. – Product / Service
Exhibits122: Amgen Inc. – Key offerings
Exhibits123: Aptevo Therapeutics Inc. – Overview
Exhibits124: Aptevo Therapeutics Inc. – Product / Service
Exhibits125: Aptevo Therapeutics Inc. – Key offerings
Exhibits126: Astellas Pharma Inc. – Overview
Exhibits127: Astellas Pharma Inc. – Product / Service
Exhibits128: Astellas Pharma Inc. – Key offerings
Exhibits129: Chugai Pharmaceutical Co. Ltd. – Overview
Exhibits130: Chugai Pharmaceutical Co. Ltd. – Product / Service
Exhibits131: Chugai Pharmaceutical Co. Ltd. – Key offerings
Exhibits132: Eli Lilly and Co. – Overview
Exhibits133: Eli Lilly and Co. – Product / Service
Exhibits134: Eli Lilly and Co. – Key offerings
Exhibits135: EPIMAB BIOTHERAPEUTICS INC. – Overview
Exhibits136: EPIMAB BIOTHERAPEUTICS INC. – Product / Service
Exhibits137: EPIMAB BIOTHERAPEUTICS INC. – Key offerings
Exhibits138: F STAR THERAPEUTICS INC. – Overview
Exhibits139: F STAR THERAPEUTICS INC. – Product / Service
Exhibits140: F STAR THERAPEUTICS INC. – Key offerings
Exhibits141: F. Hoffmann La Roche Ltd. – Overview
Exhibits142: F. Hoffmann La Roche Ltd. – Business segments
Exhibits143: F. Hoffmann La Roche Ltd. – Key news
Exhibits144: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits145: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits146: Glenmark Pharmaceuticals Ltd. – Overview
Exhibits147: Glenmark Pharmaceuticals Ltd. – Product / Service
Exhibits148: Glenmark Pharmaceuticals Ltd. – Key offerings
Exhibits149: Johnson and Johnson – Overview
Exhibits150: Johnson and Johnson – Business segments
Exhibits151: Johnson and Johnson – Key news
Exhibits152: Johnson and Johnson – Key offerings
Exhibits153: Johnson and Johnson – Segment focus
Exhibits154: Mereo BioPharma Group Plc – Overview
Exhibits155: Mereo BioPharma Group Plc – Product / Service
Exhibits156: Mereo BioPharma Group Plc – Key offerings
Exhibits157: Merus N.V. – Overview
Exhibits158: Merus N.V. – Product / Service
Exhibits159: Merus N.V. – Key offerings
Exhibits160: Inclusions checklist
Exhibits161: Exclusions checklist
Exhibits162: Currency conversion rates for US$
Exhibits163: Research methodology
Exhibits164: Validation techniques employed for market sizing
Exhibits165: Information sources
Exhibits166: List of abbreviations
|
| ※본 조사보고서 [세계의 암치료용 이중특이성 항체 시장 (2023년~2027년)] (코드 : IRTNTR72677-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 암치료용 이중특이성 항체 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
